Status:
COMPLETED
The Specificity, Sensitivity and Clinical Correlation of CBA, RIPA and ELISA in Detecting AChR and MuSK IgG of Myasthenia Gravis
Lead Sponsor:
Tianjin Medical University General Hospital
Conditions:
Detection Autoantibody of Myasthenia Gravis
Eligibility:
All Genders
1-90 years
Brief Summary
Myasthenia gravis (MG) is a neuromuscular junction (NMJ) disorder mediated by autoantibodies against AChR, MuSK or other autoantigens located at the post synaptic membrane of the neuromuscular junctio...
Detailed Description
Participants: patients with suspected MG Aim: the specificity, sensitivity, and clinical correlation of AChR and MuSK IgG detection through the CBA, ELISA, and RIPA methods. Study design: A multicen...
Eligibility Criteria
Inclusion
- Patients with compatible clinical features of weakness of skeletal muscles, including ptosis, diplopia, dysphonia, dysphagia, or limb weakness.
- Patients need to do the diagnosis of MG, requiring serum autoantibody, electrophysiological, pharmacological neostigmine test, thymic computed tomography (CT) and magnetic resonance imaging (MRI), etc in the diagnostic evaluation of MG.
Exclusion
- Patients with uncertain diagnoses or incomplete clinical data for data analysis.
- Patients with abnormal serum samples, such as hemolysis or lipemia, which will affect the detection base value and the final interpretation of CBA, RIPA and ELISA.
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
2663 Patients enrolled
Trial Details
Trial ID
NCT05219097
Start Date
January 1 2021
End Date
December 31 2022
Last Update
January 19 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital
Beijing, China, 100070
2
Tianjin Medical University General Hospital
Tianjin, China, 30000